3rd Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases Conference

3rd Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases Conference is organized by Fusion Conferences Ltd and will be held from May 07 - 10, 2025 at Avra Imperial Hotel & Conference Center, Chania, Crete, Greece.

Description:
Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, affecting nearly 1 in 9 people over 65 in the world.  While a great progress in translational and discovery research is excitingly being made, there still lack effective therapies for AD and related neurodegenerative diseases.

This planned conference intends to bring leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees and to share their vision or prospects on translational or discovery research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets, new genetic association or pathways, approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries to share clinical trial results.

Key Sessions:

• The latest on AD genetics
• Peripheral and central immune response
• Multiomic dissection of AD
• Vulnerability and resilience
• Lipid and metabolic abnormalities in AD pathogenesis
• Novel therapeutic targets
• New Biomarkers 
• AI or machine learning-based drug discovery
• Insights from molecular structures
• Brain imaging of AD brains

The significance of having this conference is to provide a unique forum for the research community focusing on translational studies geared towards therapies in AD and related neurodegenerative diseases to come together to discuss the latest advances and the future challenges in the field.

Educational Need:
Junior investigators such as graduate students or postdoctoral fellows as well as physician scientists are expected to gain knowledge on the most current therapeutic strategies in AD and the related field.  The conference will also be of interest to clinical practioners seeking updates on what developments are underway in the therapeutic pipeline for AD and the scientific basis of this research pathway.